Salarius Pharmaceuticals, Inc. (SLRX )

Currency in USD Disclaimer
$1.52 +$0.21 (16.03%)
Closed 10/15/2024
$1.3
$2.29
$1.26
$7.44

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol SLRX
  • Company Salarius Pharmaceuticals, Inc.
  • Price $1.52
  • Changes Percentage 16.03
  • Change 0.21
  • Day Low $1.3
  • Day High $2.29
  • Year High $7.44
  • Year Low $1.26
  • Market Cap $2,190,563
  • Price Avg 50 EMA (D) $1.68
  • Price Avg 200 EMA (D) $3.37
  • Exchange NASDAQ
  • Volume 7,407,704
  • Average Volume 2,358,337
  • Open $1.36
  • Previous Close $1.31
  • EPS -8.73
  • PE -0.17
  • Earnings Announcement 2024-11-07 00:00:00
  • Shares Outstanding $1,441,160

Company brief: SALARIUS PHARMACEUTICALS, INC. (SLRX )

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.

SLRX Corporation News

Income Statement